| Name | Title | Contact Details |
|---|---|---|
Matt Berkle |
Head of U.S. Compliance | Profile |
Navigator Group Purchasing is a Franklin, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oetiker Inc is a Marlette, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Osypka Medical is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bardy Diagnostics, Inc. (bardydx.com) has created a new, state-of-the-art heart monitor known as Carnation Ambulatory Monitor (CAM™) that can be worn comfortably and discreetly for up to 7 days. Unlike many other heart monitors, CAM™ can be worn during exercise or while showering. Its unique, narrow, hourglass shape makes it especially advantageous for the female anatomy. Developed on the principle that non-invasive cardiac monitoring should provide an excellent quality atrial signal, the CAM is designed to be placed along the sternum—over the heart— to optimize P-wave signal capture. The result is improved ECG resolution, providing more information about the heart rhythm which may lead to more clinically actionable diagnoses.
CVRx® is a private company located in Minneapolis, Minnesota. The company has developed proprietary active implantable technology for the treatment of high blood pressure, also referred to as hypertension, and heart failure. The CVRx senior management and technical team have many years of experience commercializing implantable medical devices. The company is supported by an outstanding board of directors and a world-class scientific advisory board, which includes thought leading physicians and scientists in the field of hypertension and heart failure. CVRx has developed an implantable device that is designed to treat high blood pressure and heart failure. This new device called Barostim neo™ is designed to trigger the body`s own natural blood flow regulation system to treat high blood pressure and heart failure. CVRx has a strong intellectual property foundation, which will protect this unique technology. Barostim neo is CE marked in Europe for the treatment of hypertension patients. It is also CE marked in Europe for the treatment of heart failure. This product is currently under clinical evaluation in the United States and Canada for the treatment of high blood pressure and heart failure.